Topics

Biomarker and Genetic Predictors of Erenumab Treatment Response

2020-02-16 17:40:49 | BioPortfolio

Summary

To explore the relationship between clinical response to erenumab and genetic biomarkers

Description

This is a phase 4 open-label study aiming to explore the relationship between clinical response to erenumab and genetic biomarkers.

Subjects with episodic or chronic migraine will be treated with Erenumab 70mg or 140mg for a 4-week baseline/screening period, followed by a 24-week treatment period.

Subjects will collect migraine-related parameters daily using an eDiary and blood samples will be collected for biomarker research. All analysis will be descriptive in nature.

Study Design

Conditions

Migraine

Intervention

Erenumab

Status

Not yet recruiting

Source

Amgen

Results (where available)

View Results

Links

Published on BioPortfolio: 2020-02-16T17:40:49-0500

Clinical Trials [526 Associated Clinical Trials listed on BioPortfolio]

A Controlled Trial of Erenumab in Migraine Prevention

Study is a phase 3 confirmatory trial intended to assess the efficacy and safety of erenumab for prevention of migraine in Japanese subjects with episodic migraine (EM) and chronic migrain...

A Functional MRI Study on Erenumab Treatment Effects in Episodic Migraine Patients

The purpose of this study is to investigate the effects of erenumab on central sensitization and brain networks connectivity of migraine patients

Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine

This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to

Efficacy and Safety of Erenumab in Pediatric Subjects With Episodic Migraine

This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to

Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine

To evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity

PubMed Articles [256 Associated PubMed Articles listed on BioPortfolio]

Erenumab safety and efficacy in migraine: A systematic review and meta-analysis of randomized clinical trials.

Erenumab is a new medicine recently approved in the United States of America for the preventive treatment of migraine among adults. We aimed to conduct a meta-analysis and evaluation of the efficacy a...

The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response.

To assess the efficacy of erenumab across the spectrum of response thresholds (≥50%, ≥75%, 100%) based on monthly migraine days (MMD) reduction in patients with chronic migraine from a 12-week, ra...

Fremanezumab inhibits vasodilatory effects of CGRP and capsaicin in rat cerebral artery - Potential role in conditions of severe vasoconstriction.

CGRP plays a major role in the pathophysiology of migraine. Concomitant, CGRP plays a role in endogenous neurovascular protection from severe vasoconstriction associated with e.g. cerebral or cardiac ...

Vestibular Migraine.

The term vestibular migraine designates recurrent vertigo that is caused by migraine. Vestibular migraine presents with episodes of spontaneous or positional vertigo lasting seconds to days that are a...

Aberrant DNA methylation pattern may enhance susceptibility to migraine: A novel perspective.

In today's world migraine is one of the most frequent disorder with an estimated world prevalence of 14.7% characterized by attacks of a severe headache making people enfeebled and imposing the big so...

Medical and Biotech [MESH] Definitions

A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)

A subtype of migraine disorder, characterized by recurrent attacks of reversible neurological symptoms (aura) that precede or accompany the headache. Aura may include a combination of sensory disturbances, such as blurred VISION; HALLUCINATIONS; VERTIGO; NUMBNESS; and difficulty in concentrating and speaking. Aura is usually followed by features of the COMMON MIGRAINE, such as PHOTOPHOBIA; PHONOPHOBIA; and NAUSEA. (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)

Serotonin antagonist used against MIGRAINE DISORDERS and vascular headaches.

A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.

A 9,10alpha-dihydro derivative of ERGOTAMINE. It is used as a vasoconstrictor, specifically for the therapy of MIGRAINE DISORDERS.

More From BioPortfolio on "Biomarker and Genetic Predictors of Erenumab Treatment Response"

Quick Search

Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...


Searches Linking to this Trial